Jeito Capital, EcoR1 Capital and Syncona led a $110m Series A round in Neogene Therapeutics.

Investment companies Jeito Capital, EcoR1 Capital and Syncona led a $110m Series A round in Neogene Therapeutics, a pre-clinical stage biotechnology company, with support from Neogene’s strategic seed investors Vida Ventures, TPG and Two River. "We are extremely pleased to have made our first investment according to plan and in such a high-quality company. Neogene’s approach perfectly aligns with Jeito’s mission to support new and established entrepreneurs aspiring to help patients in need by pioneering novel, ground-breaking medicines that rethink traditional approaches. With the depth of experience of Neogene’s leadership team, the quality of its science, and its strong new and existing investor base we believe that Neogene has significant potential to transform cancer treatment for patients around the world," Rafaèle Tordjman, Jeito Founder and CEO.